Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib plus sorafenib in first-line RAS-mutant hepatocellular carcinoma
2013-000241-39Phase 2Completed
- Sponsor
- Bayer
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of refametinib and sorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Objective response rate by central radiological assessment. Started Jun 2013; status: completed.
02
Drugs
refametinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2013-000241-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000241-39.